Interactions of gallic acid, resveratrol, quercetin and aspirin at the platelet cyclooxygenase-1 level: Functional and modelling studies

Thrombosis and Haemostasis

Volumn 102, Issue 2, 2009, Pages 336-346

  Crescente, Marilena ^a   Jessen, Gisela ^b   Momi, Stefania ^c   Höltje, Hans Dieter ^b   Gresele, Paolo ^c   Cerletti, Chiara ^a   De Gaetano, Giovanni ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Aspirin; COX 1 inhibition; Dietary polyphenols; Food drug interaction; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CYCLOOXYGENASE 1; DRUG METABOLITE; GALLIC ACID; POLYPHENOL DERIVATIVE; QUERCETIN; REACTIVE OXYGEN METABOLITE; RESVERATROL; THROMBOXANE B2; ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; MEMBRANE PROTEIN; PTGS1 PROTEIN, HUMAN; PTGS1 PROTEIN, MOUSE; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD LEVEL; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MEDITERRANEAN DIET; MOLECULAR DOCKING; MOLECULAR INTERACTION; MOLECULAR MODEL; MOLECULAR STABILITY; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RED WINE; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; ANIMAL; BIOLOGICAL MODEL; BLOOD; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; DRUG INTERACTION; ENZYMOLOGY; THERMODYNAMICS;

ANIMALS; ANTIOXIDANTS; ARACHIDONIC ACID; ASPIRIN; BLOOD PLATELETS; CYCLOOXYGENASE 1; DRUG INTERACTIONS; GALLIC ACID; HUMANS; MALE; MEMBRANE PROTEINS; MICE; MODELS, BIOLOGICAL; MODELS, MOLECULAR; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; QUERCETIN; REACTIVE OXYGEN SPECIES; STILBENES; THERMODYNAMICS;

EID: 70349212203     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-01-0057     Document Type: Article

References (50)

1. de Lorgeril M, Salen P, Martin J-L, et al. Wine Drinking and Risks of Cardiovascular Complications After Recent Acute Myocardial Infarction. Circulation 2002; 106: 1465-1469. (Pubitemid 35050871)
2. Di Castelnuovo A, Rotondo S, Iacoviello L, et al. Meta-analysis of wine and beer consumption in relation to vascular risk. Circulation 2002;105: 2836-2844. (Pubitemid 34666095)
3. Huxley RR, Neil HA. The relation between dietary flavonol intake and coronary heart disease mortality: a meta-analysis of prospective cohort studies. Eur J Clin Nutr 2003; 57: 904-908.
4. Kuriyama S, Shimazu T, Ohmori K, et al. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. J Am Med Assoc 2006; 296: 1255-1265. (Pubitemid 44394897)
5. di Giuseppe R, Di Castelnuovo A, Centritto F, et al. Regular consumption of dark chocolate is associated with low serum concentrations of C-reactive protein in a healthy Italian population. J Nutr 2008; 138: 1939-1945.
6. Sofi F, Cesari F, Abbate R, et al. Adherence to Mediterranean diet and health status: meta-analysis. Br Med J 2008; 337: a1344.
7. Manach C, Williamson G, Morand C, et al. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 2005; 81: 230S-242S.
8. Flammer AJ, Hermann F, Sudano I, et al. Dark chocolate improves coronary vasomotion and reduces platelet reactivity. Circulation 2007; 116: 2376-2382. (Pubitemid 350145072)
9. Pace-Asciak CR, Hahn S, Diamandis EP, et al. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta 1995; 235: 207-219.
10. Rotondo S, Rotilio D, Cerletti C, et al. Red wine, aspirin and platelet function. Thromb Haemost 1996; 76: 818-819. (Pubitemid 26388194)
11. Janssen K, Mensink RP, Cox FJ, et al. Effects of the flavonoids quercetin and apigenin on hemostasis in healthy volunteers: results from an in vitro and a dietary supplement study. Am J Clin Nutr 1998; 67: 255-262.
12. Pignatelli P, Pulcinelli FM, Celestini A, et al. The flavonoids quercetin and catechin synergistically inhibit platelet function by antagonizing the intracellular production of hydrogen peroxide. Am J Clin Nutr 2000;72: 1150-1155. Erratum in Am J Clin Nutr 2001; 73: 360.
13. Freedman JE, Parker C 3rd, Li L, et al. Select flavonoids and whole juice from purple grapes inhibit platelet function and enhance nitric oxide release. Circulation 2001; 103: 2792-2798.
14. Shen MY, Hsiao G, Liu CL, et al. Inhibitory mechanisms of resveratrol in platelet activation: pivotal roles of p38 MAPK and NO/cyclic GMP. Br J Haematol 2007; 139: 475-485. (Pubitemid 47512173)
15. Olas B, Saluk-Juszczak J, Wachowicz B. D-glucaro 1,4-lactone and resveratrol as antioxidants in blood platelets. Cell Biol Toxicol 2008; 24: 189-199. (Pubitemid 351311394)
16. Cerletti C, Livio M, de Gaetano G. Non-steroidal anti-inflammatory drugs react with two sites on platelet cyclo-oxygenase. Evidence from .,in vivo" drug interaction studies in rats. Biochim Biophys Acta 1982; 714: 122-128.
17. de Gaetano G, Cerletti C, Dejana E, et al. Pharmacology of platelet inhibition in humans: implications of the salicylate-aspirin interaction. Circulation 1985; 72: 1185-1193. (Pubitemid 16126797)
18. Loll PJ, Picot D, Garavito RM. The structural basis of aspirin activity inferred from the cristal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol 1995; 2: 637-643.
19. Appeldoorn CC, Bonnefoy A, Lutters BC, et al. Gallic acid antagonizes P-selectin-mediated platelet-leukocyte interactions: implications for the French paradox. Circulation 2005; 111: 106-112. (Pubitemid 40070851)
20. Burns J, Gardner PT, O'Neil J, et al. Relationship among antioxidant activity, vasodilation capacity, and phenolic content of red wines. J Agric Food Chem 2000; 48: 220-230. (Pubitemid 30120345)
21. Burow S, Valet G. Flow-cytometric characterization of stimulation, free radical formation, peroxidase activity and phagocytosis of human granulocytes with 2,7-dichlorofluorescein (DCF). Eur J Cell Biol 1987; 43: 128-133. (Pubitemid 17025028)
22. Maresca M, Colao C, Leoncini G. Generation of hydrogen peroxide in resting and activated platelets. Cell Biochem Funct 1992; 10: 79-85.
23. Krötz F, Sohn HY, Pohl U. Reactive oxygen species: players in the platelet game. Arterioscler Thromb Vasc Biol 2004; 24: 1988-1996. (Pubitemid 39482420)
24. Born GVR, Cross MJ. The aggregation of blood platelets. J Physiol 1963; 168: 178-195.
25. Pampuch A, Cerletti C, de Gaetano G. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor. Thromb Haemost 2006; 96: 767-773. (Pubitemid 44883817)
26. Lill G, Voit S, Schrör K, et al. Complex effects of different green tea catechins on human platelets. FEBS Lett 2003; 546: 265-270. (Pubitemid 36782423)
27. Rarey M, Kramer B, Lengauer T, et al. A fast flexible docking method using an incremental construction algorithm. J Mol Biol 1996; 261: 470-489. (Pubitemid 26335901)
28. Lindhal E, Hess B, van der Spoel D. GROMACS 3.0: a package for molecular simulation and trajectory analysis. J Mol Model 2001; 7: 306-317. (Pubitemid 36153547)
29. Hohlfeld T, Zimmermann N, Weber AA, et al. Pyrazolinone analgesics prevent the antiplatelet effect of aspirin and preserve human platelet thromboxane synthesis. J Thromb Haemost 2008; 6: 166-173.
30. Momi S, Pitchford SC, Alberti PF, et al. Nitroaspirin plus clopidogrel versus aspirin plus clopidogrel against platelet thromboembolism and intimal thickening in mice. Thromb Haemost 2005; 93: 535-543. (Pubitemid 40394142)
31. Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA 1975; 72: 3073-3076.
32. Livio M, Del Maschio A, Cerletti C, et al. Indomethacin prevents the long-lasting inhibitory effect of aspirin on human platelet cyclo-oxygenase activity. Prostaglandins 1982; 23: 787-796. (Pubitemid 13238162)
33. Cerletti C, Livio M, Doni MG, et al. Salicylate fails to prevent the inhibitory effect of 5,8,11,14-eicosatetraynoic acid on human platelet cyclo-oxygenase and lipoxygenase activities. Biochim Biophys Acta 1983; 759 :125-127.
34. Crescente M, Cerletti C, de Gaetano G. Gallic acid, a dietary polyphenolic component, blunts the inhibition of platelet COX-1 by aspirin: preliminary in-vitro findings. Thromb Haemost 2007; 97: 1054-1056. (Pubitemid 46939224)
35. Picot D, Loll PJ, Garavito RM. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 1994; 367: 243-249. (Pubitemid 24051139)
36. Handler N, Brunhofer G, Studenik C, et al. 'Bridged' stilbene derivatives as selective cyclooxygenase- 1 inhibitors. Bioorg Med Chem 2007; 15: 6109-6118.
37. Shahrzad S, Aoyagi K, Winter A, et al. Pharmacokinetics of gallic acid and its relative bioavailability from tea in healthy humans. J Nutr 2001; 131: 1207-1210. (Pubitemid 32275101)
38. Meng X, Maliakal P, Lu H, et al. Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J Agric Food Chem 2004; 52: 935-942.
39. Walle T, Hsieh F, DeLegge MH, et al. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004; 32: 1377-1382. (Pubitemid 39564557)
40. Seeram NP, Lee R, Heber D. Bioavailability of ellagic acid in human plasma after consumption of ellagitannins from pomegranate (Punica granatum L.) juice. Clin Chim Acta 2004; 348: 63-68. (Pubitemid 39209002)
41. Labieniec M, Gabryelak T. Interactions of tannic acid and its derivatives (ellagic and gallic acid) with calf thymus DNA and bovine serum albumin using spectroscopic method. J Photochem Photobiol B 2006; 82: 72-78. (Pubitemid 43019635)
42. Ciccarone E, Di Castelnuovo A, Salcuni M, et al. A high-score Mediterranean dietary pattern is associated with a reduced risk of peripheral arterial disease in Italian patients with Type 2 diabetes. J Thromb Haemost 2003; 1: 1744-1752.
43. Trichopoulou A, Costacou T, Bamia C, et al. Adherence to a Mediterranean diet and survival in a Greek population. N Engl J Med 2003; 348: 2599-2608. (Pubitemid 36741587)
44. Martínez-González MA, Fuente-Arrillaga CD, Nunez-Cordoba JM, et al. Adherence to Mediterranean diet and risk of developing diabetes: prospective cohort study. Br Med J 2008; 336: 1348-1351.
45. Gambino MC, Passaghe S, Chen ZM, et al. Selectivity of oral aspirin as an inhibitor of platelet vs vascular cyclooxygenase activity is reduced by portacaval shunt in rats. J Pharmacol Exp Ther 1988; 245: 287-290. (Pubitemid 18126642)
46. Konishi Y, Hitomi Y, Yoshioka E. Intestinal absorption of p-coumaric and gallic acids in rats after oral administration. J Agric Food Chem 2004; 52: 2527-2532.
47. Heptinstall S, May J, Fox S, et al. Cocoa flavanols and platelet and leukocyte function: recent in vitro and ex vivo studies in healthy adults. J Cardiovasc Pharmacol 2006; 47 (Suppl 2): S197-205. (Pubitemid 44620211)
48. Maree AO, Fitzgerald DJ. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation 2007; 115: 2196-2207. (Pubitemid 46659072)
49. Zimmermann N, Hohlfeld T. Clinical implications of aspirin resistance. Thromb Haemost 2008; 100: 379-390.
50. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361: 573-574.